.

  FOR IMMEDIATE RELEASE
Contact:  

Robert F. Apple, Chief Operating Officer
InKine Pharmaceutical Company, Inc.
215-283-6850

Donald C. Weinberger
Wolfe Axelrod Weinberger Assoc. LLC
212-370-4500, 212-370-4505 fax
[email protected]


INKINE ELECTS ROBERT F. APPLE TO ITS BOARD OF DIRECTORS

 

BLUE BELL, PA July 18, 2003 - InKine Pharmaceutical Company, Inc. (Nasdaq: INKP) today announced the election of Robert F. Apple to its Board of Directors. Mr. Apple joined InKine in November 1997 as Vice President of Finance and Administration. Since that time, his role has grown to include responsibilities for sales and manufacturing operations. Mr. Apple currently serves as both Chief Operating and Chief Financial Officer of the Company. He will continue to report directly to Leonard S. Jacob, M.D., Ph.D., InKine’s Chairman and Chief Executive Officer.

“It is with great confidence and personal pleasure that we announce Bob’s election to the Board of Directors,” said Leonard S. Jacob, M.D., Ph.D., Chairman and Chief Executive Officer of InKine. “Bob and I have worked closely together for many years developing InKine’s specialty gastrointestinal franchise. His leadership has been integral to the success of InKine. In the finance arena, Bob recently negotiated the conversion of our $13 million in convertible debt, improving our financial condition and future earnings prospects. On the commercial side, we recently received audited prescription data for May, which once again was an all-time high in terms of prescriptions filled and market share. We look forward to Bob’s contributions to our Board,” added Dr. Jacob.

About InKine Pharmaceutical
InKine Pharmaceutical Company, Inc. is a publicly traded biopharmaceutical company focused on the diagnosis and treatment of cancer and autoimmune diseases. The Company's development strategy is to acquire late-stage drug candidates with short time lines to commercialization. The Company's first product, Visicol™ is the first and only tablet purgative preparation indicated for bowel cleansing prior to colonoscopy. InKine's second product, IBStat™, is a novel oral hysocyamine spray for the treatment of Irritable Bowel Syndrome (IBS) and spasm of the colon. Additionally, the Company is developing other clinical compounds such as Colirest™, which is in clinical trials for the treatment of Crohn's disease and completed Phase II trials for the treatment of ulcerative colitis. For further information, please visit InKine on their web site http://www.inkine.com.

In addition to historical facts or statement of current condition, this press release may contain forward-looking statements. Forward-looking statements provide InKine's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential pharmaceutical products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings projections, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. InKine's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties such as those set forth in its reports on Form 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, InKine does not intend (and it is not obligated) to update publicly any forward-looking statements. This discussion is permitted by the Private Securities Litigation Reform Act of 1995.